Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical utility gene card for: Alveolar rhabdomyosarcoma.

× No keyword cloud information.

30 in total

Review 1. Pathologic classification of rhabdomyosarcomas and correlations with molecular studies.

Authors: D M Parham
Journal: Mod Pathol Date: 2001-05 Impact factor: 7.842

2. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions.

Authors: Frederic G Barr; Stephen J Qualman; Michele H Macris; Natalya Melnyk; Elizabeth R Lawlor; Donna M Strzelecki; Timothy J Triche; Julia A Bridge; Poul H B Sorensen
Journal: Cancer Res Date: 2002-08-15 Impact factor: 12.701

3. Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature.

Authors: James R Anderson; Frederic G Barr; Douglas S Hawkins; David M Parham; Stephen X Skapek; Timothy J Triche
Journal: J Clin Oncol Date: 2010-08-09 Impact factor: 44.544

4. Chromosomal translocation t(1;13)(p36;q14) in a case of rhabdomyosarcoma.

Authors: J A Biegel; R S Meek; A H Parmiter; K Conard; B S Emanuel
Journal: Genes Chromosomes Cancer Date: 1991-11 Impact factor: 5.006

5. Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee.

Authors: W M Crist; L Garnsey; M S Beltangady; E Gehan; F Ruymann; B Webber; D M Hays; M Wharam; H M Maurer
Journal: J Clin Oncol Date: 1990-03 Impact factor: 44.544

6. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.

Authors: Poul H B Sorensen; James C Lynch; Stephen J Qualman; Roberto Tirabosco; Jerian F Lim; Harold M Maurer; Julia A Bridge; William M Crist; Timothy J Triche; Frederic G Barr
Journal: J Clin Oncol Date: 2002-06-01 Impact factor: 44.544

7. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Studies I to III.

Authors: S L Wolden; J R Anderson; W M Crist; J C Breneman; M D Wharam; E S Wiener; S J Qualman; S S Donaldson
Journal: J Clin Oncol Date: 1999-11 Impact factor: 44.544

8. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1.

Authors: Marco Wachtel; Marcel Dettling; Eva Koscielniak; Sabine Stegmaier; Jörn Treuner; Katja Simon-Klingenstein; Peter Bühlmann; Felix K Niggli; Beat W Schäfer
Journal: Cancer Res Date: 2004-08-15 Impact factor: 12.701

9. Relationship of tumor-cell ploidy to histologic subtype and treatment outcome in children and adolescents with unresectable rhabdomyosarcoma.

Authors: D N Shapiro; D M Parham; E C Douglass; R Ashmun; B L Webber; W A Newton; M L Hancock; H M Maurer; A T Look
Journal: J Clin Oncol Date: 1991-01 Impact factor: 44.544

10. A specific chromosomal abnormality in rhabdomyosarcoma.

Authors: E C Douglass; M Valentine; E Etcubanas; D Parham; B L Webber; P J Houghton; J A Houghton; A A Green
Journal: Cytogenet Cell Genet Date: 1987

2 in total

1. Cytological diagnosis of metastatic alveolar rhabdomyosarcoma in the ascitic fluid: Report of a case highlighting the diagnostic difficulties.

Authors: Andrew C Nelson; Charanjeet Singh; Stefan E Pambuccian
Journal: Cytojournal Date: 2012-03-31 Impact factor: 2.091

2. Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA.

Authors: Marco Perez; Sandra Muñoz-Galván; Manuel P Jiménez-García; Juan J Marín; Amancio Carnero
Journal: Oncotarget Date: 2015-12-01

2 in total